101. The effects of oral supplements with Sambucus nigra, Zinc, Tyndallized Lactobacillus acidophilus (HA122), Arabinogalactans, vitamin D, vitamin E and vitamin C in otitis media with effusion in children: a randomized controlled trial.
- Author
-
Della Volpe A, Ricci G, Ralli M, Gambacorta V, De Lucia A, Minni A, Pirozzi C, Paccone M, Pastore V, and Di Stadio A
- Subjects
- Acoustic Impedance Tests, Administration, Oral, Ascorbic Acid administration & dosage, Ascorbic Acid therapeutic use, Audiometry, Pure-Tone, Child, Child, Preschool, Combined Modality Therapy, Female, Galactans therapeutic use, Humans, Infant, Male, Otitis Media with Effusion physiopathology, Otoscopy, Treatment Outcome, Vitamin D administration & dosage, Vitamin D therapeutic use, Vitamin E administration & dosage, Vitamin E therapeutic use, Vitamins therapeutic use, Zinc therapeutic use, Galactans administration & dosage, Lactobacillus acidophilus physiology, Otitis Media with Effusion diet therapy, Sambucus nigra chemistry, Vitamins administration & dosage, Zinc administration & dosage
- Abstract
Objective: To evaluate the ability of oral supplements with immune-stimulating molecules (Sambucus nigra, Zinc, Tyndallized Lactobacillus acidophilus (HA122), Arabinogalactans, vitamin D, vitamin E and vitamin C) to reduce the inflammation of the upper airway tract and improve the outcome of otitis media with effusion (OME) in children., Patients and Methods: Randomized controlled trial. One-hundred ninety-eight children (CI 95%: 12-96 months) were divided into four groups. Group 1 (48 subjects) received 10 ml of oral supplements (OS) with immune-stimulating molecules for three months (20 days consecutively, then 10 days of suspension - the therapeutic scheme was repeated three times); Group 2 (54 children) underwent treatment with 10 ml of OS for 90 consecutive days; Group 3 (48 subjects) received 15 ml of OS for 45 consecutive days; a control group (48 children) underwent the standard treatment for rhinitis and OME. Outcome measures included otoscopy, tympanometry, fibroendoscopy, and the pure tone audiometry (PTA) at T0 (before treatment), T1 (45 days after treatment), and T2 (90 days after treatment)., Results: All children treated with OS showed a reduction of Upper Airway Infection (UAI) episodes and OME compared to the control group independent of the administration method and posology. The three groups treated with OS showed statistically significant differences between T0 and T2 for otoscopy, tympanometry, fibroendoscopy, and PTA. In Group 2, the otoscopy and the tympanometry scores improved at T1. Group 2 and 3 had better PTA results than Group 1., Conclusions: OS with immune-stimulating molecules should be considered as a supporting therapy in children affected by recurrent episodes of UAI associated with OME due to their capacity to improve the immune response and reduce the inflammatory phenomena. OS can improve the fibroendoscopic findings by restoring middle ear ventilation, in addition to their ability to reduce inflammation in the middle ear.
- Published
- 2019
- Full Text
- View/download PDF